Compare Cytokinetics Inc (CYTK) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Financial Select Sector SPDR Fund — how do they compare? Cytokinetics Inc trades at $76.22 (market cap $10.63B), while Financial Select Sector SPDR Fund trades at $57.82. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | XLF | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | — |
52-Week High | $87.26 | $58.01 |
52-Week Low | $34.31 | $47.80 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
XLF, the Financial Select Sector SPDR ETF, trades at $57.73, down 0.14% on the day, with a bullish technical signal driven by moving averages. The ETF recently crossed above its 200-day moving average and hit a record high, supported by strong inflows into sector ETFs. A dividend of $0.19 is scheduled for June 2026.
Outlook remains positive given sector momentum and AI-driven opportunities, though overbought RSI levels and concentration risks warrant caution. Financials benefit from robust bank earnings and market broadening, but interest rate sensitivity and valuation pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
